Study for patients with IgA nephropathy
IgA Nephropathy (IgAN, also known as Berger’s disease) is a rare autoimmune disease that can slowly damage the kidneys and may eventually lead to kidney failure. Managing IgAN is challenging—sometimes overwhelming.
Vera Therapeutics is conducting a clinical study in IgAN. The ORIGIN 3 study is exploring how atacicept, the study medication, might help prevent kidney damage in people with IgAN by targeting the upstream source of disease.
Are 18 years or older
Diagnosed with IgAN, confirmed by a kidney biopsy within the past 10 years
On a stable, prescribed regimen of an ACE inhibitor or ARB medication for blood pressure for at least 3 months
**There are other criteria that potential participants must meet in order to qualify for the study**
If you’re interested in participating in one of our Research Studies:
ext 2150, 2170 or 2190